Anti-Cancer Activity of Curcumin Loaded Nanoparticles in Prostate Cancer
Researchers indicated that poly(lactic-co-glycolic acid)- curcumin (CUR) nanoparticles efficiently internalize in prostate cancer cells and release biologically active CUR in cytosolic compartment of cells for effective therapeutic activity. [Biomaterials]
Abstract
Important Role of SUMOylation of Spliceosome Factors in Prostate Cancer Cells
Using SI2 as a way of inhibiting the activity of sentrin/SUMO (small ubiquitin-like modifier)-specific proteases and the SUMO stably-transfected PC3 cells as a prostate cancer model, in combination with the stable isotope labeling with amino acids quantitative proteomic technique, scientists identified more than 900 putative target proteins of SUMO, in which 231 proteins were further subjected to bioinformatic analysis. [J Proteome Res]
Abstract
The Long Noncoding RNAs PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer
Prostate cancer-associated transcript 29 (PCAT29) knockdown significantly increased proliferation and migration of prostate cancer cells, while PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. [Mol Cancer Res]
Abstract
MLN2238 Synergizes BH3 Mimetic ABT-263 in Castration-Resistant Prostate Cancer Cells by Induction of NOXA
The antitumor efficacy of ABT-263 and MLN2238 were evaluated as single agents and in combination in four castration-resistant prostate cancer (CRPC) cell lines: PC3, C4-2B, C4-2, and DU145. Scientists found that ABT-263 and MLN2238 alone exhibited a mild cytotoxicity, and in combination, they elicited a synergistic cytotoxic effect in CRPC cells. [Tumor Biol]
Abstract
The Role of Estrogen Receptor Beta in Prostate Cancer
Estrogen receptor beta (ERβ) is a promising target as an anticancer therapy and prevention for prostate cancer. The authors review the recent experimental findings of ERβ signaling in prostate. [Mol Med]
Full Article
Visit
our reviews page to see a complete list of reviews in the prostate cell research field.
NW Bio Announces Completion of DCVAX®-Direct Phase I Trial Recruitment
Northwest Biotherapeutics announced that the Phase I portion of the Company’s Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the company is now underway with preparations for the Phase II portion of this trial, as well as expansion of DCVax-Direct manufacturing. The Phase I/II trial is testing the safety and activity of DCVax-Direct in various types of cancer. [Northwest Biotherapeutics, Inc.] Press Release
Recruit Top Talent:
Reach more than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Prostate Cell News? Click here to submit!